Management of paediatric intracranial ependymoma

Syeda Kobra Kishwar Jafri
Saqib Kamran Bakhshi
Muhammad Shahzad Shamim

Follow this and additional works at: https://ecommons.aku.edu/pakistan_fhs_mc_surg_neurosurg
Part of the Nervous System Diseases Commons, Neurology Commons, and the Neurosurgery Commons
Management of paediatric intracranial ependymoma
Syeda Kubra Kishwar Jafri, Saqib Kamran Bakhshi, Muhammad Shahzad Shamim

Abstract
Intracranial ependymoma are relatively common paediatric brain tumours, but their eloquent location and high recurrence rate pose a significant challenge. Gross total resection or maximum safe resection followed by adjuvant radiotherapy are currently the standard recommended treatment, although there is still nearly 50% recurrence risk at 5 years. Chemotherapy has shown some promising results after recent advances in molecular understanding of ependymomas, but needs further evaluation before it could be added to the treatment regime.

Keywords: Intracranial Ependymoma, Pediatric, Surgical Management.

Introduction
Ependymoma are neuroepithelial tumours, and comprise 8-10% of all paediatric tumours.1 They are predominantly located in the brain in the posterior fossa (70% of the cases), but can be found in the supratentorial region and the spinal cord.2 Intracranial ependymoma are commonly present in the ventricles, but they can also occur in the cerebral cortex in the vicinity of the ependymal lining of the ventricles, and rarely can be purely cortical with no connection to the ventricular wall (Figure-1).3,4 The WHO classification system classifies ependymomas into 3 grades. Grade I are benign (myxopapillary), grade II tumours are also benign and can be divided into 4 sub-types (cellular, papillary, clear-cell and tanycytic), and grade III are malignant tumours (anaplastic). Historically, age at diagnosis, extent of surgical resection and pathological subtypes were considered important prognostic factors. However, there are incongruities in literature regarding relative importance of these clinical parameters. We have reviewed the literature to assess the current recommendations on the management of intracranial ependymomas, and to draw conclusions with regards to the outcomes.

Review of Evidence
Several factors influence the most appropriate management and outcomes of children with intracranial ependymomas. Surgical resection has been the mainstay of treatment with multiple objectives including tissue diagnosis, removing the mass effect from important neural structures and to open the CSF pathways for relieving hydrocephalus. However, complete excision poses a challenge considering eloquent location of these tumours. Consequently, gross total resection (GTR) is possible in only up to 50% of the cases.5 Perilongo et al., had reviewed 92 children with ependymomas for extent of resection, and had reported better overall survival after GTR (69.8%) as compared to subtotal resection (STR) (32.5%).6 They had also reported that GTR group had a better impact on progression free survival (57% vs 11%).6 Similar conclusions were drawn by Horn et al., in a series of 83 patients.7 They reported that failure to achieve GTR, histological grade III tumours and less than 3 years age at diagnosis were all factors that resulted in adverse outcomes in childhood intracranial ependymomas.7

Cage et al., published a systematic review on outcomes in childhood intracranial ependymomas after combining extent of resection and histological grade.8 Patients with grade II ependymomas had better survival after GTR alone than with any other treatment modality. In patients with grade III ependymomas, STR with adjuvant radiation was associated with better outcomes than GTR. This was attributed to the fact that grade III tumours were more infiltrative with poorer anatomical boundaries, and thus, aggressive resection to achieve GTR caused more morbidity and resulted in poorer neurological outcomes, as compared to STR.8

In a large multi-center retrospective analysis of 463 patients, Amanda et al., reviewed children with grade II and III
intracranial ependymomas with long clinical and radiological follow-ups. Extent of resection, tumour sub-type and type of treatment were significantly associated with better overall survival in their study. GTR was superior to STR for 5-year survival (75 ± 5% vs. 54 ± 8%; p = 0.002). However, there was high recurrence rate within 10 years of diagnosis which brought overall survival to 61 ± 7% at 10 years; so GTR was not curative for all children. They proposed that GTR alone is not sufficient to treat children with intracranial ependymomas and recommended adjuvant treatments after surgery for better outcomes. Some studies have also proposed 'second-look' surgery for residual ependymomas, however, a large cohort published by Italian investigators found no long-term significant difference in outcomes of children who underwent single surgery with adjuvant therapy, and those who underwent 'second-look' surgery. Although radiation alone does not have a significant role in treatment of ependymomas, it has been shown to improve survival when coupled with surgical resection, particularly in cases where GTR is not possible, as shown in the study by Cage et al. Adjuvant radiotherapy is now part of the standard treatment protocol at most centers for children more than 3 years of age. Historically, prophylactic radiation was also administered to the whole neural axis to prevent recurrence. However, it has not proven to be of any benefit in preventing recurrence and distal metastasis. The St Jude RT-1 trial had recruited 88 children with ependymomas who were administered radiation and followed up for a median of 38.2 months. They concluded that limited volume local irradiation results in good disease control (3-year progression-free survival estimate was 74.7% 5.7%).

Chemotherapy till date, does not have a clearly defined role in management of intracranial ependymoma. Several studies have tried to assess the role of different regimens including vincristine, cyclophosphamide, etoposide, platinum derivatives and methotrexate, with promising results, but none have been able to post outcomes better than adjuvant radiotherapy. Its use is therefore currently limited to recurrent tumours not amenable for surgical resection. Nearly half the children with intracranial ependymomas will develop recurrence within five years, despite GTR and adjuvant radiation. Most of these recurrences are at the primary tumour site. The recommended treatment protocol for recurrent ependymomas involves surgical resection wherever possible and re-irradiation often using proton-beam therapy, with some centers including chemotherapy as well.

**Conclusion**

Extent of resection is the prime prognostic factor followed by age at presentation, both of which have a direct relation to the favourability of outcomes. GTR followed by adjuvant focal radiation remains the optimal choice for paediatric cranial ependymomas and has significantly improved the overall survival and progression-free survival over 5 years follow ups.

**References**